Carvedilol increases two-year survival in dialysis patients with dilated cardiomyopathy: A prospective, placebo-controlled trial

Journal of the American College of Cardiology

Volumn 41, Issue 9, 2003, Pages 1438-1444

  Cice, Gennaro ^a   Ferrara, Luigi ^a   D'Andrea, Antonello ^a   D'Isa, Salvatore ^a   Di Benedetto, Attilio ^b   Cittadini, Antonio ^c   Elvira Russo, Pina ^a   Golino, Paolo ^a   Calabrò, Raffaele ^a  

^a SECOND UNIVERSITY OF NAPLES   (Italy)

^b Naples NephroCare Group   (Italy)

^c UNIVERSITY OF NAPLES FEDERICO II   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CARVEDILOL; DIGITALIS; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; NITRATE;

ADULT; ARTICLE; BETA ADRENERGIC RECEPTOR BLOCKING; BRADYCARDIA; BRONCHOSPASM; CONGESTIVE HEART FAILURE; CONTROLLED STUDY; DRUG EFFECT; ECHOCARDIOGRAPHY; FEMALE; FOLLOW UP; HEART DILATATION; HEMODIALYSIS PATIENT; HUMAN; HYPOTENSION; MAJOR CLINICAL STUDY; MALE; MORBIDITY; MORTALITY; PRIORITY JOURNAL; SURVIVAL; VERTIGO;

EID: 0038408916     PISSN: 07351097     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0735-1097(03)00241-9     Document Type: Article

References (23)

1. Packer M, Bristow MR, Cohn JN, et al. The effect of carvedilol on morbidity and mortality in patients with chronic heart failure: U.S. Carvedilol Heart Failure study group. N EngI J Med 1996;334:1349-55.
2. CIBIS II Investigators and Committees. The Cardiac Insufficiency Bisoprolol Study (CIBIS-II): a randomized trial. Lancet 1999;349:9-13.
3. MERIT-HF Study Group. Effects of metoprolol CR/XL in chronic heart failure: Metoprolol CR/XL Randomised Intervention Trial in Congestive Heart Failure (MERIT-HF). Lancet 1999;353:2001-7.
4. Luke RG. Chronic renal failure - a vasculopathic state. N Engl J Med 1998;339:841-3.
5. U.S. Renal Data System: 1999 annual data report. Am J Kidney Dis 1999;34:S1.
6. Valderrabano F, Berthoux FC, Jones EHP, et al. Report on management of renal failure in Europe. XXV, 1994: end-stage renal disease and dialysis report. Nephrol Dial Transplant 1996;11:2-21.
7. Cice G, Ferrara L, Di Benedetto A, et al. Dilated cardiomyopathy in dialysis patients: a double-blind, placebo-controlled trial. J Am Coll Cardiol 2001;37:407-11.
8. Stack A, Bloembergen WE. Congestive heart failure among incident US dialysis patients: predictors and clinical correlates (abstr). J Am Soc Nephrol 1998;9:226A.
9. Harnett JD, Foley RN, Kent GM, et al. Congestive heart failure in dialysis patients: prevalence, incidence, prognosis, and risk factors. Kidney Int 1995;47:884-90.
10. Locatelli F, Del Vecchio L, Manzoni C. Morbidity and mortality on maintenance haemodialysis. Nephron 1998;80:380-400.
11. Goodman WG, Goldin J, Kuizon BD, et al. Coronary-artery calcification in young adults with end-stage renal disease who are undergoing dialysis. N Engl J Med 2000;342:1478-83.
12. Raggi P. Imaging of cardiovascular calcifications wlth electron beam tomography in hemodialysis patients. Am J Kidney Dis 2001;37 Suppl 2:S62-5.
13. Cice G, Tagliamonte E, Ferrara L, et al. Efficacy of carvedilol on complex ventricular arrhythmias in dilated cardiomyopathy: double-blind, randomized, placebo-controlled study. Eur Heart J 2000;21:1259-64.
14. Converse RL, Jacobsen TN, Toto RD, et al. Sympathetic overactivity in patients with chronic renal failure. N Engl J Med 1992;327:1912-8.
15. Remuzzi G. Sympathetic overactivity in hypertensive patients with chronic renal disease. N Engl J Med 1999;340:1360-1.
16. Zoccali C, Mallamaci F, Parlongo S, et al. Plasma norepinephrine predicts survival and incident cardiovascular events in patients with end-stage renal disease. Circulation 2002;105:1354-9.
17. Cice G, Di Benedetto A, Tagliamonte E, et al. A comparative study of carvedilol and controlled release nifedipine in the management of hypertension in chronic haemodialyzed patients. High Blood Pressure 1997;6:217-21.
18. Cice G, Tagliamonte E, Ferrara L, et al. Complex ventricular arrhythmias and carvedilol: efficacy in uremic hemodialyzed patients. Cardiologia 1998;43:597-604.
19. Cice G, Di Benedetto A, Aquino D, et al. Comparison of the effects of carvedilol and diltiazem on silent myocardial ischemia in chronic hemodialysis patients. Giorn It Nefrol 1997;14:389-96.
20. Gehr TW, Tenero DM, Boyle DA, et al. The pharmacokinetics of carvedilol and its metabolites after single and multiple dose oral administration in patients with hypertension and renal insufficiency. Eur J Clin Pharmacol 1999;55:269-77.
21. Fuerstein GZ, Hamburger SA, Smith EF III, et al. Myocardial protection with carvedilol. J Cardiovasc Pharmacol 1992;19:5138-41.
22. Pertosa G, Grandaliano G, Gesualdo L, et al. Clinical relevance of cytokine production in hemodialysis. Kidney Int 2000;76:S104-11.
23. Feuerstein GZ, Ruffolo RR Jr. Carvedilol, a novel vasodilating beta-blocker with the potential for cardiovascular organ protection. Eur Heart J 1996;17:S24-9.